Comparative Pharmacology
Head-to-head clinical analysis: GYNAZOLE 1 versus VAGISTAT 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNAZOLE 1 versus VAGISTAT 1.
GYNAZOLE-1 vs VAGISTAT-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butoconazole nitrate, an imidazole antifungal agent, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing fungal cell membrane permeability.
Tioconazole is an imidazole antifungal that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and fungal growth.
One 100 mg vaginal ovule inserted intravaginally as a single dose.
One 300 mg vaginal suppository administered as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 days after intravaginal administration, reflecting slow absorption from the vaginal mucosa and prolonged retention in tissues.
The terminal elimination half-life is approximately 5-7 days, reflecting prolonged vaginal retention and slow systemic absorption.
Primarily as unchanged drug in feces via biliary elimination; <1% excreted renally as metabolites.
Approximately 50% is excreted unchanged in feces via biliary elimination; less than 1% is excreted unchanged in urine.
Category C
Category C
Azole Antifungal
Azole Antifungal